Enstilar in Combination With Enbrel or Humira for Plaque Psoriasis
| Status: | Recruiting |
|---|---|
| Conditions: | Psoriasis |
| Therapuetic Areas: | Dermatology / Plastic Surgery |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 2/6/2019 |
| Start Date: | January 16, 2019 |
| End Date: | December 15, 2019 |
| Contact: | Jerry Bagel, MD |
| Email: | dreamacres1@aol.com |
| Phone: | 6094434500 |
An Open-Label Study Evaluating Enstilar® (Calcipotriene and Betamethasone Dipropionate) Foam, 0.005%/0.064% QD in Psoriasis Patients Being Treated With Etanercept or Adalimumab
4 weeks of adjunctive therapy of Enstilar® QD followed by 12 weeks QOD to patients with 2-10%
BSA who are receiving etanercept or adalimumab for at least 24 weeks
BSA who are receiving etanercept or adalimumab for at least 24 weeks
30 subjects treated with etanercept or adalimumab for at least 24 weeks with a body surface
area 2-10% and physician global assessment greater than or equal to 2 will receive Enstilar®
once daily for 4 weeks followed by QOD for 12 weeks.
area 2-10% and physician global assessment greater than or equal to 2 will receive Enstilar®
once daily for 4 weeks followed by QOD for 12 weeks.
Inclusion Criteria:
- Male or female adult ≥ 18 years of age;
- Diagnosis of chronic plaque-type
- Patient with 2-10% BSA
- Physician Global Assessment of 2 or greater
- Patient has been treated with etanercept or adalimumab for a minimum of 24 weeks
Exclusion Criteria:
- ˂2 or >10% BSA
- PGA <2
- Patient not receiving etanercept or adalimumab, or receiving etanercept or adalimumab
<24weeks
We found this trial at
1
site
59 One Mile Road
East Windsor, New Jersey 08520
East Windsor, New Jersey 08520
609-443-4500
Principal Investigator: Jerry Bagel, MD
Click here to add this to my saved trials
